# Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

Study · id `cardio:ct-nct01541943` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01541943](<https://clinicaltrials.gov/study/NCT01541943>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01541943

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.

## Technical summary

Registry record NCT01541943. Randomized; double masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2014-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 356 participants (enrolled count; ClinicalTrials.gov record NCT01541943, source copy `cardio:ctgov-nct01541943-2015-09-23`, retrieved 2026-10-26)
- Start date: 2012-03 (registry gives no type) (ClinicalTrials.gov record NCT01541943, source copy `cardio:ctgov-nct01541943-2015-09-23`, retrieved 2026-10-26)
- Primary completion: 2014-11 (actual) (ClinicalTrials.gov record NCT01541943, source copy `cardio:ctgov-nct01541943-2015-09-23`, retrieved 2026-10-26)
- Completion: 2014-11 (actual) (ClinicalTrials.gov record NCT01541943, source copy `cardio:ctgov-nct01541943-2015-09-23`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01541943, source copy `cardio:ctgov-nct01541943-2015-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01541943-2015-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
- Condition: Essential Hypertension
- Condition: Hyperlipidemia
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Losartan
- Intervention (Drug): Placebo
- Intervention (Drug): HL-040XC
- Lead sponsor: HanAll BioPharma Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)

## Provenance

Content hash: 0b62b36c7a3373f39b90b7ba7be2adea71e22c789e3d63ca21e36234c23759b8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
